retinal diseases

View All

retinal disease pipeline portfolio
Boehringer Ingelheim ties up with Inflammasome Therapeutics

Boehringer Ingelheim and Inflammasome Therapeutics Inc. have announced that they have entered into a definitive a co-development and license agreement to develop therapies for the patients with retinal diseases.The deal is about jointly developing three novel therapies for retinal diseases with the help of Inflamma...

Find More